ArticlePakistan journal of medical sciences2024
Outcome analysis of differentiated thyroid cancer: Experience from tertiary care in Karachi.
Article in Pakistan journal of medical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [SENP1 reduces ferroptosis of thyroid cancer cells by regulating hypoxia-inducible factor-1α].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Although differentiated thyroid cancers have a good prognosis overall, their incidence is on the rise with extremely limited data available in our region. The objective was to describe the outcomes of differentiated thyroid carcinoma in a tertiary care hospital. Methods: This was a retrospective study conducted at Aga Khan University Hospital. The data was collected by reviewing the charts and reports of patients (1999-2011) diagnosed with differentiated thyroid cancer. Information regarding the demographic status, type of differentiated thyroid cancer, stage at the time of presentation, and the outcome was noted. The study endpoints were the disease cure, persistence, and recurrence. Results: Most of the patients were diagnosed with papillary carcinoma stage-I (49.0%) having a cure rate of 52.94%, a persistence rate of 28.43%, and a recurrence rate of 18.62%. A 33.3% of patients with follicular carcinoma at stage-4 had zero cure rate, the persistence rate was 25% and the recurrence rate was also 25%. In patients with hurthle cell variant of follicular carcinoma; the majority (60.0%) were diagnosed at stage-I having a cure rate of 80%. The persistence rate was 0%, and the recurrence rate was 20%. Conclusion: This study highlights the low cure rate while describing the high rate of disease persistence and recurrence. This can be due to delays related to the diagnosis and scarcity of proper treatment. Recognition of this emergent disease is vital so that curative methods prescribed at proper time can diminish the morbidity and mortality linked with this treatable cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.